Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

HIV and fatty liver: a hidden link under the microscope

NCT ID NCT07737340

Knowledge-focused Sponsor: Yaşar Bayındır, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study follows 250 people newly diagnosed with HIV and 161 healthy volunteers over five years to see who develops metabolic fatty liver disease (MASLD). Researchers use annual blood tests, ultrasounds, and FibroScans to measure liver fat and stiffness. The goal is to uncover risk factors that make people with HIV more prone to liver problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could identify early risk factors for fatty liver disease in people with HIV, potentially guiding future prevention or monitoring strategies.
What could go wrong
This is an observational study, not a treatment trial, so it won't test any intervention. Results may take years and might not lead to direct clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 411 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

he study population consists of 411 adult participants (≥ 18 years of age) who are citizens of the Republic of Türkiye, enrolled across 9 different clinical centers nationwide (Adana, Ankara, Antalya, Diyarbakır, Gaziantep, İstanbul, İzmir, Kocaeli, and Şanlıurfa). The population is divided into two distinct cohorts: a patient group comprising 250 newly diagnosed individuals living with HIV who are initiating Antiretroviral Therapy (ART), and a comparative control group comprising 161 healthy, HIV-negative individuals.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (For the Patient Group / Newly Diagnosed HIV+): * Citizens of the Republic of Türkiye * Adults (≥ 18 years of age) * Confirmed Anti-HIV positive (Newly diagnosed) * Patients who are initiating Antiretroviral Therapy (ART) Inclusion Criteria (For the Healthy Control Group / HIV-): * Citizens of the Republic of Türkiye * Adults (≥ 18 years of age) * Confirmed Anti-HIV negative Exclusion Criteria: * There are no specified exclusion criteria for this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fatty liver are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fatty liver disease HIV infectious disease metabolic dysfunction-associated steatohepatitis metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fatty liver HIV infections Metabolic dysfunction-associated steatotic liver disease (masld) & steatohepatitis (MASH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Adana Acıbadem Hospital

    RECRUITING

    Adana, Turkey (Türkiye)

  • Akdeniz University, Faculty of Medicine

    RECRUITING

    Antalya, Turkey (Türkiye)

  • Cukurova University, Faculty of Medicine

    RECRUITING

    Adana, Turkey (Türkiye)

  • Dicle University, Faculty of Medicine

    RECRUITING

    Diyarbakır, TR21280, Turkey (Türkiye)

  • Ege University, Faculty of Medicine

    RECRUITING

    Izmir, Turkey (Türkiye)

  • Gaziantep University, Faculty of Medicine

    RECRUITING

    Gaziantep, Turkey (Türkiye)

  • Guven Hospital

    RECRUITING

    Ankara, Ankara, 06850, Turkey (Türkiye)

  • Hacettepe University, Faculty of Medicine

    RECRUITING

    Ankara, Turkey (Türkiye)

  • Harran University, Faculty of Medicine

    RECRUITING

    Sanliurfa, Turkey (Türkiye)

  • Health Sciences University Hamidiye Faculty of Medicine

    RECRUITING

    Istanbul, Turkey (Türkiye)

  • Kocaeli University, Faculty of Medicine

    RECRUITING

    Kocaeli, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.